Valganciclovir
- Generic Name
- Valganciclovir
- Brand Names
- Valcyte
- Drug Type
- Small Molecule
- Chemical Formula
- C14H22N6O5
- CAS Number
- 175865-60-8
- Unique Ingredient Identifier
- GCU97FKN3R
- Background
Valganciclovir hydrochloride (Valcyte, manufactured by Roche) is an antiviral medication used to treat cytomegalovirus infections. As the L-valyl ester of ganciclovir, it is actually a prodrug for ganciclovir. After oral administration, it is rapidly converted to ganciclovir by intestinal and hepatic esterases.
- Indication
Valganciclovir is an antiviral medication used for the treatment of cytomegalovirus infections.
- Associated Conditions
- Cytomegalovirus (CMV) Infections, Cytomegalovirus Retinitis
- Associated Therapies
- -
Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2016-05-04
- Last Posted Date
- 2016-05-16
- Lead Sponsor
- Chang Gung Memorial Hospital
- Target Recruit Count
- 18
- Registration Number
- NCT02761291
- Locations
- 🇨🇳
Chang-Gung Memorial Hospital, Linkou, Taoyuan, Taiwan
Evaluation of the Benefit of Antiviral Treatment With Valganciclovir on Congenital CMV Infection-related Deafness on Hearing and Balance
- First Posted Date
- 2015-11-17
- Last Posted Date
- 2019-11-18
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 1
- Registration Number
- NCT02606266
- Locations
- 🇫🇷
Robert Debré Hospital, Paris, France
A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus
- Conditions
- Interventions
- First Posted Date
- 2015-05-12
- Last Posted Date
- 2021-07-16
- Lead Sponsor
- Chimerix
- Target Recruit Count
- 6
- Registration Number
- NCT02439957
- Locations
- 🇺🇸
Yale New Haven Hospital, New Haven, Connecticut, United States
🇺🇸University of Colorado Hospital/Health Science Center, Aurora, Colorado, United States
🇺🇸St. Vincent Medical Center, Los Angeles, California, United States
A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus Disease
- Conditions
- Interventions
- First Posted Date
- 2015-05-12
- Last Posted Date
- 2021-07-16
- Lead Sponsor
- Chimerix
- Target Recruit Count
- 5
- Registration Number
- NCT02439970
- Locations
- 🇺🇸
St. Vincent Medical Center, Los Angeles, California, United States
🇺🇸University of Colorado Hospital/Health Science Center, Aurora, Colorado, United States
🇺🇸Yale New Haven Hospital, New Haven, Connecticut, United States
Congenital Cytomegalovirus: Efficacy of Antiviral Treatment
- Conditions
- Interventions
- First Posted Date
- 2013-12-09
- Last Posted Date
- 2021-06-03
- Lead Sponsor
- Dr. Ann C.T.M. Vossen
- Target Recruit Count
- 37
- Registration Number
- NCT02005822
- Locations
- 🇳🇱
Department Medical Microbiology, Leiden, Zuid Holland, Netherlands
ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation
- Conditions
- Interventions
- First Posted Date
- 2013-10-30
- Last Posted Date
- 2022-04-12
- Lead Sponsor
- University of Minnesota
- Target Recruit Count
- 137
- Registration Number
- NCT01972035
- Locations
- 🇺🇸
University of MN, Minneapolis, Minnesota, United States
A Study on Spermatogenesis in Male Renal Transplant Recipients Receiving Valganciclovir (Valcyte®) Versus Untreated Matched Controls
- First Posted Date
- 2012-08-13
- Last Posted Date
- 2018-08-31
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 59
- Registration Number
- NCT01663740
- Locations
- 🇺🇸
Tufts Medical Center, Boston, Massachusetts, United States
🇺🇸University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸University of California at San Francisco, San Francisco, California, United States
Congenital Cytomegalovirus: Efficacy of Antiviral Treatment in a Randomized Controlled Trial
- Conditions
- Interventions
- First Posted Date
- 2012-08-01
- Last Posted Date
- 2015-06-18
- Lead Sponsor
- Dr. Ann C.T.M. Vossen
- Target Recruit Count
- 2
- Registration Number
- NCT01655212
- Locations
- 🇳🇱
Department Medical Microbiology, Leiden University Medical Center, Leiden, Zuid Holland, Netherlands
Valganciclovir Therapy in Infants and Children With Congenital CMV Infection and Hearing Loss
- First Posted Date
- 2012-07-25
- Last Posted Date
- 2024-10-16
- Target Recruit Count
- 54
- Registration Number
- NCT01649869
- Locations
- 🇺🇸
Children's of Alabama Child Health Research Unit (CHRU), Birmingham, Alabama, United States
🇺🇸University of Rochester Medical Center, Rochester, New York, United States
🇺🇸Children's National Medical Center - Sheikh Zayed Campus - Infectious Disease, Washington, District of Columbia, United States
CMV Antiviral Prevention Strategies in D+R-Liver Transplants ("CAPSIL")
- First Posted Date
- 2012-03-13
- Last Posted Date
- 2021-08-26
- Target Recruit Count
- 205
- Registration Number
- NCT01552369
- Locations
- 🇺🇸
Ronald Reagan University of California Los Angeles Medical Center, Los Angeles, California, United States
🇺🇸Mayo Clinic, Rochester - Infectious Diseases, Rochester, Minnesota, United States
🇺🇸Emory Clinic - Transplant Center, Atlanta, Georgia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.